Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 9, 2009

Axxora to Distribute Olink’s Duolink Protein Interaction and Detection Platform in North America

  • Research reagents supply company Axxora negotiated North American distribution rights to Sweden-based Olink Bioscience’s Duolink® reagent product line. The Duolink products are based on Olink’s in situ PLA™ (proximity ligation assay) technology, which the company claims enables researchers to detect and individually count single endogenous proteins, protein-protein interactions, and protein phosphorylations in fixed cells and tissue samples.

    The PLA technology hinges on two unique bi-functional PLA probes, each of which consists of an antibody attached to a unique synthetic oligonucleotide reporter. The approach requires positive identification of two different epitopes on the same protein or complex. This results in what Olink claims to be profoundly enhanced specificity compared with assays that depend on single-binding recognition.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »